On January 19, 2023 the Honourable Filomena Tassi, Minister of the Federal Economic Development Agency for Southern Ontario, on behalf of the Honourable Jean-Yves Duclos, Minister of Health, announced a new investment to support one clinical trials consortium, seven training platforms, and 22 research projects. This is Canada’s largest-ever investment in clinical trials.
Approximately $60M is being awarded to 22 projects to fund clinical trial phases, designs, and objectives that align with the priorities of the Biomanufacturing and Life Sciences Strategy, including two UBC-led projects for a total of over $5.5 million.
Funded UBC-LED Projects
- A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal Investigator: Kevin A. Hay (Medicine)
Funding Stream: Clinical Trial Projects - Randomized Embedded Multifactorial Adaptive Platform Trial of Community Acquired Pneumonia
Principal Investigator: Srinivas Murthy (Pediatrics)
Funding Stream: Clinical Trial Projects